Over the past two decades, contributing to the development of new drugs in biopharma, Tomas grew increasingly frustrated with the lack of accurate models and tools for predicting how a drug will fare when it is finally tested in the clinic. Tomas ultimately founded Leapfrog Bio to tackle this challenge head on. Past experience includes leading computational and methods development groups at Merck, Celgene, and BMS to help bridge the gap between genomics and drug development, as well as leading an academic group as an Assistant Professor focusing on mapping noncoding driver genes.
Past experience includes leading computational and methods development groups at Merck, Celgene, and BMS to help bridge the gap between genomics and drug development, as well as leading an academic group as an Assistant Professor focusing on mapping noncoding driver genes.

Peter has devoted the better part of his career to studying cancer biology; contributing to ground-breaking insights on metastasis, chemoresistance, and tumor driver mechanisms. Peter leads our chemogenomic development and screening efforts. He loves the outdoors and is a year-round biker (in Canada!).

Originally from Pittsburgh, Jessica moved to the San Francisco Bay Area in 2008 and never left. During her tenure at Stanford (BS in Biology, PhD in Genetics), Jessica tackled a diverse set of complex biological questions in regeneration, stem cell biology, and molecular evolution by thoughtfully employing a suite of genomic tools. Jessica is excited to funnel her broad knowledge base into the incredibly impactful work at Leapfrog Bio. Suffice it to say that she's come a long way since making a mock laboratory in the corner of her garage at age 12, where she "observed" roses wither in the dark.
Jessica is excited to funnel her broad knowledge base into the incredibly impactful work at Leapfrog Bio. Suffice it to say that she's come a long way since making a mock laboratory in the corner of her garage at age 12, where she "observed" roses wither in the dark.

Doris' initial research focused on developing new molecular approaches to visualize neurodevelopment. She quickly discovered her flair for methods development, and this has been instrumental throughout her career, including developing infectious disease diagnostics and understanding drug mechanism of action.

A recent graduate from the Biotechnology program at St. Lawrence College, Robin is utilizing his valuable molecular skills to advance our screening operations. When not experimenting in the lab, Robin enjoys experimenting in the kitchen or playing ultimate frisbee.

An experienced data guru, Mike contributes through his mix of valuable expertise, which includes bioinformatics, networking IT, visual compute cluster administration, web-hosting, and data management. When not working, Mike enjoys fishing.